Sign in
CompletedNo phase

Restrictive Use of Restraints and Delirium Duration in ICU

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
423 people enrolled
Started
25 Jan 2021
Ended
8 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Systematic use group
  • Restrictive use group
Record updated
23 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients fulfilling all the following criteria will be eligible:
  • Adults ≥ 18 years
  • MV expected for at least ≥ 48 hours
  • Invasive MV in the ICU for a duration inferior to 6 hours
  • eligible to prescription for physical contention

Who cannot take part

  • Documented delirium prior to ICU admission according to the CAM-ICU
  • History of dementia (Mini mental test < 24)
  • Alcoholic withdrawal syndrome expected
  • Admission for any neurological disease including post-cardiopulmonary resuscitation (including cardiac arrest, stroke, traumatic brain injury, meningoencephalitis, and status epilepticus)
  • Serious auditory or visual disorders
  • Patients meeting one of the following criteria will not be considered for inclusion:
  • Unable to understand French
  • Pregnant or lactating women
  • SAPS II > 65 points at screening
  • Do-not-resuscitate orders (advance directives)
  • No affiliation to a social security regime (beneficiary or assignee)
  • Patient or person of confidence (if present at the time of inclusion) opposing the patient's participation in research
  • Patient already involved in another interventional clinical research whose main objective is related to delirium

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The R2D2-ICU study will be a prospective, parallel-group, open label, multicenter (6 centers) randomized controlled trial. All consecutive eligible patients will be included. Patients will be randomly assigned (1/1 ratio) to either systematic PR use (systematic use group) or restrictive PR use (restrictive use group). Patients in the restrictive PR group will be subjected to PR only in case of severe agitation defined by a RASS ≥ +3. Physical restraint will consist of wrist straps. In both groups, patients will receive standardized management for analgesia, sedation, delirium detection, weaning and early mobilization according to current guidelines. Concealment will be obtained using a computer-generated randomization scheme of various-sized blocks stratified by center, age (< or ≥ 65 years) and coma at the beginning of invasive mechanical ventilation (D0)) through a centralized 24h/24h internet service. Investigation blinded to group assignment is not feasible. In both arms, patients' arousal will be evaluated twice a day until day 14 with the use of RASS. Patients with a RASS of -5 or -4 will be considered comatose (and will not be assessed for delirium). Patients with a RASS score ≥ -3 will be assessed for delirium with the use of the CAM-ICU scale twice a day.

The 2 groups in the trial

  • Systematic use groupExisting treatment, for comparison
  • Restrictive use groupTreatment being tested

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Restrictive Use of Restraints and Delirium Duration in ICU: a Randomized Controlled Trial
Publications
Record updated
23 March 2026